Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission: individual-patient-data meta-analysis of seven trials
Phase meta-analysisN = 987
- Population
- Patients with small-cell lung cancer in complete remission
- Design
- Meta-analysis of individual patient data from seven trials comparing prophylactic cranial irradiation (PCI) with no PCI. The main endpoint was survival. The abstract does not state the stage of disease.
- Primary endpoint
- OS
- Arms
- Prophylactic cranial irradiation (experimental): Prophylactic cranial irradiation (total doses in the pooled trials: 8 Gy, 24 to 25 Gy, 30 Gy, 36 to 40 Gy)
- No prophylactic cranial irradiation (control): No prophylactic cranial irradiation
- People
- Aupérin A, senior author Aisner J, Prophylactic Cranial Irradiation Overview Collaborative Group
Δ 36-month OS+5.4 points
Show the numbers
| Endpoint | Analysis | Prophylactic cranial irradiation | No prophylactic cranial irradiation | Effect |
|---|---|---|---|---|
| OS987 patients in seven trials (individual patient data) | primaryAupérin 1999 | 20.7% at 3 y | 15.3% at 3 y | P=0.01Relative risk of death 0.84 (95% CI 0.73 to 0.97); this is a relative risk as published, not entered as a hazard ratio. Survival at 3 years: 20.7% with PCI vs 15.3% without. |
| Endpoint | Analysis | Prophylactic cranial irradiation | No prophylactic cranial irradiation | Effect |
|---|---|---|---|---|
| OS987 patients in seven trials (individual patient data) | primaryAupérin 1999 | 20.7% at 3 y | 15.3% at 3 y | P=0.01Relative risk of death 0.84 (95% CI 0.73 to 0.97); this is a relative risk as published, not entered as a hazard ratio. Survival at 3 years: 20.7% with PCI vs 15.3% without. |